Evaluating third-line therapies in refractory metastatic colorectal cancer: a systematic review and network meta-analysis
GastroenterologiaSobre o estudo
- Desenho
- Revisão sistemática
- Nível de evidência
- 1 · Evidência consolidada
- Revista
- Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
- Publicado em
- 28 out 2025
- Citações
- 2
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Evaluating third-line therapies in refractory metastatic colorectal cancer: a systematic review and network meta-analysis
Celine Hoyek, Syed Arsalan Ahmed Naqvi, Oudai Sahvan, Fares Jamal, Kunwer Sufyan Faisal, Angelo Pirozzi, Surabhi Pathak, Diana Almader-Douglas, Mitesh J Borad, Christina Wu et al.
Descritores MeSH
- Colorectal Neoplasms
- Antineoplastic Combined Chemotherapy Protocols
- Ramucirumab
- Drug Combinations
- Humans
- Neoplasm Metastasis
- Phenylurea Compounds
- Pyridines
- Pyrrolidines
- Thymine
Veja também
Estudos relacionados
- Health-related quality of life in patients with KRASG12C-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial
- Efficacy and safety of TAS-102 followed by regorafenib or reverse sequence in later-line treatment of metastatic colorectal cancer: a systematic review and meta-analysis
- A systematic review of cost-effectiveness studies of later-line treatments for refractory metastatic colorectal cancer
- Trifluridine-tipiracil plus bevacizumab versus trifluridine-tipiracil monotherapy for chemorefractory metastatic colorectal cancer: a systematic review and meta-analysis